Pancreatic cancer ‘mismatch’ in Lynch syndrome

OBJECTIVE: Immune therapy with the PD1 inhibitor pembrolizumab has been approved to treat unresectable/metastatic solid tumours exhibiting mismatch repair (MMR) deficiency. Lynch syndrome (LS), caused by autosomal dominant germline mutations of a MMR gene, predisposes to the development of MMR-defic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendifar, Andrew E, Larson, Brent K, Rojansky, Rebecca, Guan, Michelle, Gong, Jun, Placencio, Veronica, Tuli, Richard, Hitchins, Megan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6577306/
https://www.ncbi.nlm.nih.gov/pubmed/31275582
http://dx.doi.org/10.1136/bmjgast-2019-000274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6577306/
https://www.ncbi.nlm.nih.gov/pubmed/31275582
http://dx.doi.org/10.1136/bmjgast-2019-000274

Ejemplares similares